Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close.

Rhea-AI Summary

Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close. A conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET.

According to Halozyme, the call requires pre-registration and will be available via live webcast and replay in the company's Investors section at www.halozyme.com.

Argus May 1 session

+0.47% close to close Open Argus

Details

News Market Reaction – HALO

On May 1, the first trading day after this news, HALO closed 0.47% above the previous close.

Data tracked by StockTitan Argus for the May 1 session.

Market Context

This announcement sets the schedule for Halozyme’s first quarter 2026 results on May 11, 2026, with ...

Analysis

This announcement sets the schedule for Halozyme’s first quarter 2026 results on May 11, 2026, with a conference call at 1:30pm PT / 4:30pm ET. It follows February’s report of record $1.397 billion in 2025 revenue and reiterated 2026 guidance of $1.71–$1.81 billion in revenue. Investors may focus on how Q1 performance tracks against those targets and on updates related to recent collaborations and pipeline or platform contributions.

Key Figures

Earnings release date: May 11, 2026 Conference call time: 1:30pm PT / 4:30pm ET FY 2025 revenue: $1.397 billion +5 more

Earnings release date

May 11, 2026

Q1 2026 financial and operating results release after close

Conference call time

1:30pm PT / 4:30pm ET

Q1 2026 results discussion on May 11, 2026

FY 2025 revenue

$1.397 billion

Full-year 2025 total revenue reported Feb 17, 2026

Royalty revenue

$867.8 million

Full-year 2025, +52% year-over-year

2026 revenue guidance

$1.71–$1.81 billion

Full-year 2026 guidance reiterated Feb 17, 2026

2026 adj. EBITDA

$1.125–$1.205 billion

Full-year 2026 guidance

2026 non-GAAP EPS

$7.75–$8.25

Full-year 2026 guidance

Upfront payment

$15 million

Vertex collaboration for Hypercon™ technology announced Apr 7, 2026

Previous Earnings date Reports

1 past event · Latest: Feb 10

Same Type 1 event

1. Feb 10

   Earnings date notice

   24h Move

   -0.9%

   Announced Q4 and full-year 2025 results date and investor call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May 11, 2026, following the close of trading.

Halozyme will host a conference call on Monday, May 11, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/178516398?pwd=q41k1S5t

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-first-quarter-2026-financial-and-operating-results-302759415.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Halozyme (HALO) report Q1 2026 results?

Halozyme will report first quarter 2026 results on Monday, May 11, 2026 after market close. According to Halozyme, the company will release financial and operating results then and discuss them on a scheduled conference call later that day.

What time is the Halozyme (HALO) Q1 2026 conference call?

The conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET. According to Halozyme, management will discuss the results on the call and a live webcast and replay will be available afterward.

How can investors access the Halozyme (HALO) earnings call webcast?

Investors may access the live webcast by pre-registering via the provided events link and via Halozyme's Investors website. According to Halozyme, the webcast and a replay will be available in the Investors section at www.halozyme.com.

Is pre-registration required to join Halozyme's (HALO) live conference call?

Pre-registration is required to access the live conference call via the event link provided by Halozyme. According to Halozyme, pre-registration details are available through the supplied Q4 events URL and the Investors section of the company's website.

Where will the Halozyme (HALO) earnings replay be posted after the call?

The replay will be posted in Halozyme's Investors section at www.halozyme.com after the call. According to Halozyme, both a live webcast and a subsequent replay of the conference call will be available on the corporate website.

Will Halozyme (HALO) discuss operating as well as financial results on the May 11 call?

Yes; Halozyme announced it will report both financial and operating results and discuss them on the conference call. According to Halozyme, the company will present its first quarter 2026 financial and operating update during the May 11 call.